![]() |
|
|
Vol. 284, Issue 2, 599-605, February 1998
Division of Pharmaceutics and Biopharmaceutics, The purpose of this study was to determine if lipid transfer protein
(LTP I) regulates the plasma lipoprotein distribution of cyclosporine
(CSA). Experimental strategies that involved the supplementation and
inhibition of LTP I were used to test these hypotheses. Incubation of
CSA with human plasma supplemented with exogenous LTP I resulted in a
significantly greater percentage of CSA recovered in the high-density
lipoprotein (HDL)/lipoprotein deficient plasma (LPDP) fraction than in
the low-density lipoprotein (LDL)/very low-density lipoprotein (VLDL)
fraction compared to plasma which had no exogenous LTP I added.
Incubation of radiolabeled cholesteryl ester (CE) or CSA-enriched HDL
or LDL in T150 buffer supplemented with LTP I resulted in a
significantly greater percentage of CE than CSA being transferred from
HDL to LDL and LDL to HDL. However, the percent transfer from LDL to
HDL was significantly lower for CE than CSA when these particles were
incubated in LPDP that contained endogenous LTP I. The percent transfer
of CE from HDL to LDL and LDL to HDL was significantly decreased in the
presence of TP2, a monoclonal antibody directed against LTP I, compared to controls. The percent transfer of CSA from LDL to HDL was
significantly decreased in the presence of TP2. However, the percent
transfer of CSA from HDL to LDL in the presence of TP2 was not
significantly different compared to controls. These findings suggest
that the transfer of CSA between HDL and LDL is only partially
facilitated through LTP I CE transfer activity.
0022-3565/98/2842-0599$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
K. M. Wasan, O. Sivak, R. A. Cote, A. I. MacInnes, K. D. Boulanger, M. Lynn, W. J. Christ, L. D. Hawkins, and D. P. Rossignol Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2796 - 2803. [Abstract] [Full Text] [PDF] |
||||